Abstract
This article discusses standard and new disruptive strategies in the race to develop an anti-COVID-19 vaccine. We also included new bioinformatic data from our group mapping immunodominant epitopes and structural analysis of the spike protein. Another innovative approach reviewed here is the use of BCG vaccine as priming strategy and/or delivery system expressing SARS-CoV-2 antigens.
Keywords:
BCG; COVID-19; RBD domain; SARS-CoV-2; Vaccines.
Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiotensin-Converting Enzyme 2 / chemistry
-
Antibodies, Viral / immunology
-
BCG Vaccine / administration & dosage*
-
COVID-19 / immunology*
-
COVID-19 / prevention & control
-
COVID-19 Vaccines / immunology*
-
Epitope Mapping
-
Humans
-
Middle East Respiratory Syndrome Coronavirus / chemistry
-
Protein Binding
-
SARS-CoV-2 / immunology*
-
Spike Glycoprotein, Coronavirus / chemistry
-
Spike Glycoprotein, Coronavirus / immunology*
-
Vaccines, DNA / immunology*
-
Viral Vaccines / immunology*
Substances
-
Antibodies, Viral
-
BCG Vaccine
-
COVID-19 Vaccines
-
Spike Glycoprotein, Coronavirus
-
Vaccines, DNA
-
Viral Vaccines
-
spike glycoprotein, SARS-CoV
-
spike protein, SARS-CoV-2
-
Angiotensin-Converting Enzyme 2